平扫低密度作为LI-RADS CT辅助特征对肝细胞癌的诊断价值
本回顾性研究纳入194例有HCC风险的成人共328个肝脏病灶,评估平扫低密度作为CT辅助特征诊断HCC的价值。平扫低密度与HCC相关(诊断比值比9.1,95%CI 4.9–16.6,P<.001);加入该特征后LR-4中HCC比例从64.7%升至72.2%,敏感度从79.9%升至88.6%(P<.001),特异度无显著差异(82.7% vs 85.0%,P=.06)。
要点
- 平扫低密度与HCC相关,诊断比值比9.1(95%CI 4.9–16.6,P<.001)。
- 加入平扫低密度后,LR-4中HCC比例从64.7%(22/34)升至72.2%(39/54)。
- 加入平扫低密度后敏感度从79.9%(146/187)升至88.6%(163/187)(P<.001),特异度无显著差异(82.7% vs 85.0%,P=.06)。
核心结论
- 将CT平扫低密度作为附加辅助特征可提高LR-4中HCC的比例,并提高LI-RADS诊断HCC的敏感度。
研究设计与样本
- 回顾性研究,纳入2022年1月至12月在一家三级转诊机构行多期动态肝脏CT后接受肝切除或肝移植的有HCC风险成人194例(平均年龄59岁±10[SD],159名男性),共328个肝脏病灶。
关键影像表现/征象
- 平扫低密度定义为目标肝脏病灶的密度低于肝实质(基于视觉评估)。
- 加入平扫低密度后,20个病灶(17个HCC和3个异型增生结节)从LR-3升级至LR-4,LR-4中HCC比例从64.7%(22/34)升至72.2%(39/54)。
诊断标准与关键数值
- 参考标准为组织病理学分析和临床评估;LI-RADS分类:LR-3为恶性中等概率,LR-4为可能HCC,LR-5为确定HCC。
- 平扫低密度诊断HCC的诊断比值比为9.1(95%CI 4.9–16.6;P<.001)。
- 仅用辅助特征时敏感度79.9%(146/187)、特异度85.0%(124/141);辅助特征加平扫低密度时敏感度88.6%(163/187)、特异度82.7%(121/141);敏感度差异P<.001,特异度差异P=.06。
临床应用与阅片要点
- 判读CT肝脏病灶时,可将平扫低密度作为附加辅助特征纳入LI-RADS分类以辅助诊断HCC。
- 加入平扫低密度可使部分LR-3病灶升级为LR-4,并提高LR-4中HCC的比例。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Current CT ancillary features (AFs) have limitations, as several AFs are more evident at MRI. Precontrast low attenuation may serve as a potential AF in the Liver Imaging Reporting and Data System (LI-RADS). Purpose To evaluate the diagnostic value of precontrast low attenuation at CT as an additional AF for diagnosing hepatocellular carcinoma (HCC) and to assess its impact on LI-RADS diagnostic performance. Materials and Methods This retrospective study included adults at risk of HCC who underwent multiphase dynamic liver CT before hepatic resection or liver transplant at a tertiary referral facility between January and December 2022. Two radiologists assessed the presence of major features and AFs for each hepatic observation on the basis of LI-RADs categories, as follows: LR-3, intermediate probability of malignancy; LR-4, probably HCC; and LR-5, definitely HCC. Each lesion was assigned a LI-RADS category twice: first, by using AFs only (LI-RADS category with AFs only) and next, by using AFs with precontrast low attenuation (LI-RADS category with AFs and precontrast low attenuation). Precontrast low attenuation was defined as an attenuation of the target hepatic observation lower than that of the liver parenchyma based on visual assessment. Histopathologic analysis and clinical assessment were used as reference standards. The diagnostic performance of the two LI-RADS strategies was compared using generalized estimating equations. Results A total of 194 patients (mean age, 59 years ± 10 [SD]; 159 men) with 328 hepatic observations were included: 187 (57.0%) HCCs, 26 (7.9%) non-HCC malignancies, and 115 (35.1%) benign lesions. Precontrast low attenuation was associated with HCCs, yielding a diagnostic odds ratio of 9.1 (95% CI: 4.9, 16.6; P < .001). Adding precontrast low attenuation upgraded 20 observations (17 HCCs and three dysplastic nodules) from LR-3 to LR-4, increasing the proportion of HCCs in LR-4 from 64.7% (22 of 34) to 72.2% (39 of 54). Compared with LR with AFs only, LR with AFs and precontrast low attenuation had a higher sensitivity (88.6% [163 of 187] vs 79.9% [146 of 187]; P < .001), with no evidence of a difference in specificity (82.7% [121 of 141] vs 85.0% [124 of 141]; P = .06). Conclusion Applying precontrast low attenuation at CT as an additional AF increased the proportion of HCCs in LR-4 and improved the sensitivity of LI-RADS for diagnosing HCC. © RSNA, 2025 Supplemental material is available for this article.
引用
- Park R, Choi ES, Byun JH, et al. Diagnostic Value of Precontrast Low Attenuation as a LI-RADS CT Ancillary Feature for Hepatocellular Carcinoma. Radiology. 2025. PMID: 41288480. doi:10.1148/radiol.251598
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。